Cilostazol pretreatment prevents PTSD-related anxiety behavior through reduction of hippocampal neuroinflammation
- 29 June 2023
- journal article
- research article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 397 (1) , 133-144
Abstract
Current pharmacological treatments against post-traumatic stress disorder (PTSD) lack adequate efficacy. As a result, intense research has focused on identifying other molecular pathways mediating the pathogenesis of this condition. One such pathway is neuroinflammation, which has demonstrated a role in PTSD pathogenesis by causing synaptic dysfunction, neuronal death, and functional impairment in the hippocampus. Phosphodiesterase (PDE) inhibitors (PDEIs) have emerged as promising therapeutic agents against neuroinflammation in other neurological conditions. Furthermore, PDEIs have shown some promise in animal models of PTSD. However, the current model of PTSD pathogenesis, which is based on dysregulated fear learning, implies that PDE inhibition in neurons should enhance the acquisition of fear memory from the traumatic event. As a result, we hypothesized that PDEIs may improve PTSD symptoms through inhibiting neuroinflammation rather than long-term potentiation-related mechanisms. To this end, we tested the therapeutic efficacy of cilostazol, a selective inhibitor of PDE3, on PTSD-related anxiety symptoms in the underwater trauma model of PTSD. PDE3 is expressed much more richly in microglia and astrocytes compared to neurons in the murine brain. Furthermore, we used hippocampal indolamine 2,3-dioxygenase 1 (IDO) expression and interleukin 1 beta (IL-1β) concentration as indicators of neuroinflammation. We observed that cilostazol pretreatment prevented the development of anxiety symptoms and the increase in hippocampal IDO and IL-1β following PTSD induction. As a result, PDE3 inhibition ameliorated the neuroinflammatory processes involved in the development of PTSD symptoms. Therefore, cilostazol and other PDEIs may be promising candidates for further investigation as pharmacological therapies against PTSD.Keywords
This publication has 79 references indexed in Scilit:
- Evaluation of Antidepressant and Anxiolytic Activity of Phosphodiesterase 3 Inhibitor - CilostazolIndian Journal of Psychological Medicine, 2012
- Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developmentsBritish Journal of Pharmacology, 2012
- Molecular and cell signaling targets for PTSD pathophysiology and pharmacotherapyNeuropharmacology, 2012
- Hippocampal dysfunction effects on context memory: Possible etiology for posttraumatic stress disorderNeuropharmacology, 2012
- Reduced hippocampal and amygdala activity predicts memory distortions for trauma reminders in combat-related PTSDJournal of Psychiatric Research, 2011
- Posttraumatic Stress Disorder and Health-Related Quality of Life in Patients With Coronary Heart DiseaseArchives of General Psychiatry, 2009
- The use of the elevated plus maze as an assay of anxiety-related behavior in rodentsNature Protocols, 2007
- Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey ReplicationArchives of General Psychiatry, 2005
- ANP inhibits TNF-α-induced endothelial MCP-1 expression—involvement of p38 MAPK and MKP-1Journal of Leukocyte Biology, 2003
- Suppression of IL-12 production by phosphodiesterase inhibition in murine endotoxemia is IL-10 independentEuropean Journal of Immunology, 1998